KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Common Equity (2016 - 2025)

Historic Common Equity for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $838.3 million.

  • Neogenomics' Common Equity fell 769.87% to $838.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $838.3 million, marking a year-over-year decrease of 769.87%. This contributed to the annual value of $902.3 million for FY2024, which is 416.32% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Common Equity is $838.3 million, which was down 769.87% from $854.0 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Common Equity ranged from a high of $1.1 billion in Q2 2021 and a low of $838.3 million during Q3 2025
  • Over the past 5 years, Neogenomics' median Common Equity value was $947.4 million (recorded in 2023), while the average stood at $969.3 million.
  • In the last 5 years, Neogenomics' Common Equity surged by 7552.84% in 2021 and then plummeted by 1092.61% in 2022.
  • Over the past 5 years, Neogenomics' Common Equity (Quarter) stood at $1.1 billion in 2021, then fell by 9.95% to $998.0 million in 2022, then fell by 5.66% to $941.5 million in 2023, then decreased by 4.16% to $902.3 million in 2024, then dropped by 7.1% to $838.3 million in 2025.
  • Its Common Equity was $838.3 million in Q3 2025, compared to $854.0 million in Q2 2025 and $888.3 million in Q1 2025.